NVCT Insider Trading (Nuvectis Pharma)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $565,748.85
Insider Selling (Last 12 Months): $0.00
Nuvectis Pharma Share Price & Price History
Current Price: $19.00
Price Change: ▲ Price Increase of +0.15 (0.80%)
As of 05/16/2022 05:00 PM ET
The Safest Option in Trades!
From Tradewins | Ad
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.
And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!
Nuvectis Pharma Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/12/2022 | Kenneth Hoberman | Director | Buy | 6,000 | $17.40 | $104,400.00 | 55,140 |  |
| 5/12/2022 | Kenneth Hoberman | Director | Buy | 6,000 | $17.40 | $104,400.00 | 55,140 | |
| 5/12/2022 | Ron Bentsur | CEO | Buy | 12,245 | $16.99 | $208,042.55 | 2,957,704 | |
| 5/12/2022 | Shay Shemesh | Insider | Buy | 1,278 | $15.85 | $20,256.30 | 1,240,893 | |
| 3/28/2022 | Ron Bentsur | CEO | Buy | 4,000 | $7.05 | $28,200.00 | | |
| 3/17/2022 | Ron Bentsur | CEO | Buy | 7,000 | $7.63 | $53,410.00 | | |
| 2/14/2022 | Ron Bentsur | CEO | Buy | 8,000 | $5.88 | $47,040.00 | | |
How You Should Be Choosing Your Stocks
From Vantage Point | Ad
Grab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades.
We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2.
Click here now to join and get access to our forecasting.
SEC Filings (Institutional Ownership Changes) for Nuvectis Pharma (NASDAQ:NVCT)
Nuvectis Pharma Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 5/12/2022 | BlackRock Inc. | 7,872 | $59K | 0.0% | N/A | 0.062% |  |
| 5/11/2022 | Ronit Capital LLP | 550,000 | $4.08M | 5.1% | N/A | 4.325% | |
Data available starting January 2016
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of targeted small molecule therapeutics for the treatment of cancer. The company develops NXP800, an oral small molecule inhibitor of the Heat Shock Factor 1 pathway, a signaling pathway in the initiation and progression of various cancers; and NXP900 program, an oral small molecule designed to inhibit the SRC and YES1 kinases. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Read More on Nuvectis Pharma
Today's Range
Now: $19.00
52 Week Range
Now: $19.00
Volume
34,758 shs
Average Volume
48,246 shs
Market Capitalization
$241.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Nuvectis Pharma?
Who are the major institutional investors of Nuvectis Pharma?
Which major investors are buying Nuvectis Pharma stock?
In the previous quarter, NVCT stock was acquired by institutional investors including:
- Ronit Capital LLP
- BlackRock Inc.
In the previous year, these company insiders have bought Nuvectis Pharma stock:
- Ron Bentsur (CEO)
- Shay Shemesh (Insider)
- Kenneth Hoberman (Director)
Learn More investors buying Nuvectis Pharma stock.
